Exceptional Leaders Series

Thermo Fisher: The Company Behind the Science

October 1, 2026
Watch, Listen and Subscribe:
Video

Thermo Fisher: The Company Behind the Science

October 1, 2026

Most people don’t interact with Thermo Fisher Scientific firsthand. Still, the company's tools, services and manufacturing capabilities underpin many of the advances that define modern life, from new medicines and diagnostic tests that keep us healthy, to the materials and semiconductors that power the digital economy.

 

In this episode of Exceptional Leaders, Morgan Stanley’s Head of Life Science Tools and Diagnostics Research, Kallum Titchmarsh, visits Thermo Fisher's biologics and gene-therapy manufacturing facility in Plainville, Massachusetts, for a conversation with the company’s Chairman and CEO Marc Casper. They discuss how Thermo Fisher helps turn discovery into medicine at every stage, and how AI, automation and a relentless customer focus could accelerate the breakthroughs ahead.

    

MARC CASPER

My mother used to say to me, “We're born with two ears and one mouth, and there's a reason for that.” I think we have a culture in the organization that’s very much about listening, understanding, so that we have real clarity about what those big ideas are and then passionately going after making them a reality to help our customers do their important work. So, we're the company that helps make the world a healthier place.

 

KALLUM TITCHMARSH

Most people never encounter Thermo Fisher Scientific directly, but its products, technologies, services and manufacturing sit behind many of the scientific advances that shape modern life. From the medicines we take and the tests that doctors rely on to the advanced materials and semiconductors powering the digital world. Two decades ago, Thermo Fisher looked very different. Its roots were largely in lab products and scientific instruments. Then under chairman and CEO Mark Casper, who took the helm in 2009, the company expanded dramatically. Today, Thermo Fisher is now a key partner in everything from research to manufacturing. In a time where science grows increasingly complex. As Morgan Stanley's head of life science tools and diagnostics research, I cover the so-called picks and shovels of drug development. I wanted to know how AI is changing that toolkit and how Casper decides where to invest next. So, I travel to Thermo Fisher Biologics and gene therapy manufacturing facility in Plainville, Massachusetts, to ask him.

 

KALLUM TITCHMARSH

Marc, thank you so much for having us out here at this wonderful facility.

 

MARC CASPER

Kallum, thanks. It's really a pleasure to be able to have this conversation with you today.

 

KALLUM TITCHMARSH

If you had a minute to explain why this company matters to over day lives, what would you say.

 

MARC CASPER

We’re the company behind the scenes, and our mission is around enabling our customers to make the world a healthier place. And that enablement can be seen in developing breakthrough diagnostics that a pediatrician or your primary care physician would use to diagnose a complex disease all the way through helping the pharmaceutical and biotech industry identify the new breakthrough medicines. And we take them from the molecule all the way through the commercial production of those medicines, rely on our technologies, our people, our services, really around bringing medicines to patients.

 

KALLUM TITCHMARSH

When you took over the company in 2009, this was largely a business addressing the life sciences research community with consumables. You've since spanned way beyond that. What inspired that shift and talk us through your game plan?

MARC CASPER

we are a customer-focused, customer-centric organization deeply ingrained in customer success, because in our industry, customers are working on ten-year journeys to bring a medicine to market, or they're working on their life's research. And so that intimacy really is important. You get new ideas, and you become a trusted partner. We've been able to both organically invest in our business to expand our offerings, but also, we’ve deployed meaningful capital to be able to grow our business. And over time, we expanded our product offering, becoming a leading company in, you know, high-technology reagents, and then we added electron microscopy, so we kind of filled out the suite of laboratory-based technologies and then ultimately expanded our services offering to help our customers be able to produce medicines and manage complexity and then ultimately execute the clinical trials to determine the safety and efficacy of those medicines. It has all been a journey methodically executed to just help our customers be successful.

 

KALLUM TITCHMARSH

How do you stay connected with all your customers?

 

MARC CASPER

Probably somewhere in the range of a third of my time is purely on seeing customers, interacting in different ways to understand reality, right? How are we doing? What are the biggest unmet challenges that a customer is facing? Where can we be helpful? How are they thinking about the future? Right? And constantly across the leadership team and all of our colleagues, our customers know that fundamentally, we truly care about their success and we are an extension of their organization.

 

VOICE OVER: KALLUM TITCHMARSH

Drug development has grown far more complex. New approaches like cell gene therapy carry enormous promise. But turning those scientific breakthroughs into medicines requires specialized infrastructure and expertise. Thermo Fisher has increasingly expanded its capabilities to help customers manage that complexity.

 

KALLUM TITCHMARSH

Any examples come to mind from feedback driving maybe a major change in the business?

 

MARC CASPER

You know, we have been involved in the development and production of medicines for over 20 years. And over time, through the intensive interactions with our customers, what we saw was there were more modalities and more complexity coming into the biotech and pharmaceutical industry, because it wasn't just a monoclonal antibody, it wasn't just small molecule, but all of a sudden you have cell therapies and gene therapies.

And what those customers wanted was a partner that could help them manage their complexity, so they wouldn't have to be an expert in everything. And that allowed us ultimately to acquire Patheon in 2017. We could give it the resources. And the facility we're in today here in Massachusetts is one of the largest gene therapy sites in the world, and it's a site that we built from the ground up to meet customer demand. And ultimately, what you'll see here is not only, you know, the production of medicines, but you'll also see our collaboration center. You'll see how our technologies are used and how our customers can do their application work in a production setting.

 

VOICE OVER: KALLUM TITCHMARSH

Scale matters at a site like this, designed to move promising therapies from development into production and strip out the bottlenecks where time is measured in patient outcomes. That capability was put to a historic test during the Covid-19 pandemic, when Thermo Fisher mobilized across the company to expand production and support global testing almost overnight.

 

KALLUM TITCHMARSH

Maybe we can cast our mind back to 2020. Covid was obviously a really important time. How did you lead your employees through that pivot? And I'm curious whether Covid has changed the way you're thinking about the next hypothetical crisis.

 

MARC CASPER

As leaders, our job was to help shape priorities and give the team the resources they needed to be successful. And that backbone allowed us to do some extraordinary things as an organization and made a really big impact on society. Prior to the pandemic, you know, in a good year, we might be producing somewhere between 10 and 100,000 tests, right? Right? And ultimately, during the pandemic, we produced about a billion. What was special is that the team that does that work actually defined the problem set properly. So what the team figured out is, you know, what was the order of magnitude of the number of tests that might be needed to really get the pandemic under control? When you have that problem defined, you want it with a totally different set of solutions. We did some things that in six weeks, we had a factory producing stuff that you'd never be able to do in normal times. But society needed help and governments were supportive and ultimately we were able to step up to the moment and help in our small way of making a difference.

 

KALLUM TITCHMARSH

On this Thermo Fisher evolution, acquisitions have been an important part of that. What makes a company a Thermo Fisher company, and which parts of the operating model and culture and non-negotiable?

 

MARC CASPER

We've been an active acquirer over the last 20 plus years. And, you know, the way we think about it is ‘Does a company that we might acquire, does it really make the company stronger?’ And most importantly, ‘will customers value it?’ Right. When they read the press release, will their reaction be, ‘Oh that's interesting. That's an important field for me.

I want to learn more’ or is it more skeptical? And it starts with culture. Is there great pride in doing, you know, excellent work? Is it a well-run business? Right? What we're not looking to do is take broken businesses. We're looking at taking businesses and actually grow them more quickly, to expose them to more customers, to help them have the resources to scale more quickly. And it's not that we parachute a bunch of existing colleagues into the business, but we give the existing teams the resources to be successful. And it's worked well, right? And, you know, on day one of an acquisition, maybe the most important message that we give our teams are, ‘The day you joined the original company was the day you joined Thermo Fisher.’ It's not today on the day one. And we want to learn from you, and we want to benefit from your experience, and that collaboration and ownership, it really unlocks incredible potential. And we closed a meaningful acquisition in March of a company called Clario. It's used to be a technology provider for clinical development. And when you're doing a clinical study, it's really important to very easily understand how a patient is reacting to a medicine.

 

KALLUM TITCHMARSH

You have a pretty large business outside of healthcare too. Maybe tell us a bit about that.

 

MARC CASPER

You'll find our technology is used in helping environmental monitoring on the cleaner side across the world. Our technologies are used to control pollution. Technology’s electron microscopes are used to develop the next generation of semiconductors that power AI, and we're behind the scenes making that happen. The electron microscope is used in biology, but the core detection engine has many different applications.

 

KALLUM TITCHMARSH

I'm sure you're seeing a lot of demand from that at the moment.

 

MARC CASPER

Certainly with everything going on in AI, the demand is super robust for our semiconductor-related products.

 

KALLUM TITCHMARSH

One major challenge in healthcare over the next decade, what would that be and what role do you think Thermo Fisher can play in that?

 

MARC CASPER

The two things that we think a lot about and we're very engaged on is the neurodegenerative diseases, the Alzheimer's of the world and cancer. Both my mother and my older sister passed away from melanoma some years ago. And to see the breakthroughs that are available today for that disease where it was effectively a death sentence to today it is a treatable disease. You know, there are so many other cancers that are not yet in that field, and what we want to do is help our customers make as much progress as possible. So when you get that phone call or you get that message on a doctor's portal saying, you know, we need to talk, you know, you want the next sentence to say, you have this or this, but there’s a therapy out there that's going to be able to help you get through this and navigate it well. And that inspires all of us to be our very best.

 

KALLUM TITCHMARSH

Marc, I hear you were a hockey team manager at college.

 

MARC CASPER

Yeah. One of the fun things about being a manager is you quickly learn that the magic happens when the team works together. It's never about the individual, but it's about how well people collaborate and bring the best out in each other. And ultimately, that's what drives performance.

 

KALLUM TITCHMARSH

What’s the thing that, you know, you've specifically learned from that experience that you've brought into Thermo Fisher today?

 

MARC CASPER

From both the managerial and leadership perspective, you know, you serve the colleagues. You try to help them with priorities and give them the resources to be successful and in a way, stay out of the way and let them do their great work.

 

KALLUM TITCHMARSH

Indeed.

 

VOICE OVER: KALLUM TITCHMARSH

Every expansion has served the same goal, helping customers work faster, generate better data, and get breakthroughs to patients sooner. Now, like much of the industry, Thermo Fisher is looking at artificial intelligence to take more friction out of that process. You partnered with OpenAI. What can Thermo Fisher do today that it couldn't do two years ago?

 

MARC CASPER

What they're helping us do is deploy AI to make a meaningful difference to our customers. Right? So if I think about it at a high level, there's really three areas, right, which is our services business, our product business and then how we run the company. In our services business really around clinical development, you know, running clinical trials, just mining all of our historical data to identify which sites enroll patients better than others. And what that allows a customer to do is shave time out, shave cost out. Our clinical research associates will be supported by kind of an AI agent to help them make their work more effective. And so we're deploying the technologies very aggressively to help improve the process. In a way you can think about it as better, cheaper, faster. So that's area one. Area two is really around Nvidia. And as a leading provider of analytical instruments used to detect proteins to detect molecular interactions, what customers want to do is a much more high-volume set of experiments. And the more automated and the more AI-enabled our instruments are, the more insights that our customers get. And you're seeing a lot of demand for this automated type laboratory to be able to run very high-volume experimentation so that our customers are getting smarter. And then the final area is how we run the company. You know, Thermo Fisher is all about continuous improvement. We have a business system called Practical Process Improvement. We all wake up today as a colleague at the company. And basically our focus is how are we better today than we were yesterday? But the efficiency that we're getting to run the company better is quite compelling. We're just trying to be able to take lower value-added things out of the system and reinvest in things that really matter, R&D, application support, high-quality products and services, and it's a big part of our effort to make Thermo Fisher Scientific the best company it can possibly be.

 

KALLUM TITCHMARSH

Well, thank you so much, Marc. Incredible discussion. Really insightful. We really appreciate it.

 

MARC CASPER

Kallum, thanks for having me. It was really a pleasure this morning.

Transcript

    

MARC CASPER

My mother used to say to me, “We're born with two ears and one mouth, and there's a reason for that.” I think we have a culture in the organization that’s very much about listening, understanding, so that we have real clarity about what those big ideas are and then passionately going after making them a reality to help our customers do their important work. So, we're the company that helps make the world a healthier place.

 

KALLUM TITCHMARSH

Most people never encounter Thermo Fisher Scientific directly, but its products, technologies, services and manufacturing sit behind many of the scientific advances that shape modern life. From the medicines we take and the tests that doctors rely on to the advanced materials and semiconductors powering the digital world. Two decades ago, Thermo Fisher looked very different. Its roots were largely in lab products and scientific instruments. Then under chairman and CEO Mark Casper, who took the helm in 2009, the company expanded dramatically. Today, Thermo Fisher is now a key partner in everything from research to manufacturing. In a time where science grows increasingly complex. As Morgan Stanley's head of life science tools and diagnostics research, I cover the so-called picks and shovels of drug development. I wanted to know how AI is changing that toolkit and how Casper decides where to invest next. So, I travel to Thermo Fisher Biologics and gene therapy manufacturing facility in Plainville, Massachusetts, to ask him.

 

KALLUM TITCHMARSH

Marc, thank you so much for having us out here at this wonderful facility.

 

MARC CASPER

Kallum, thanks. It's really a pleasure to be able to have this conversation with you today.

 

KALLUM TITCHMARSH

If you had a minute to explain why this company matters to over day lives, what would you say.

 

MARC CASPER

We’re the company behind the scenes, and our mission is around enabling our customers to make the world a healthier place. And that enablement can be seen in developing breakthrough diagnostics that a pediatrician or your primary care physician would use to diagnose a complex disease all the way through helping the pharmaceutical and biotech industry identify the new breakthrough medicines. And we take them from the molecule all the way through the commercial production of those medicines, rely on our technologies, our people, our services, really around bringing medicines to patients.

 

KALLUM TITCHMARSH

When you took over the company in 2009, this was largely a business addressing the life sciences research community with consumables. You've since spanned way beyond that. What inspired that shift and talk us through your game plan?

MARC CASPER

we are a customer-focused, customer-centric organization deeply ingrained in customer success, because in our industry, customers are working on ten-year journeys to bring a medicine to market, or they're working on their life's research. And so that intimacy really is important. You get new ideas, and you become a trusted partner. We've been able to both organically invest in our business to expand our offerings, but also, we’ve deployed meaningful capital to be able to grow our business. And over time, we expanded our product offering, becoming a leading company in, you know, high-technology reagents, and then we added electron microscopy, so we kind of filled out the suite of laboratory-based technologies and then ultimately expanded our services offering to help our customers be able to produce medicines and manage complexity and then ultimately execute the clinical trials to determine the safety and efficacy of those medicines. It has all been a journey methodically executed to just help our customers be successful.

 

KALLUM TITCHMARSH

How do you stay connected with all your customers?

 

MARC CASPER

Probably somewhere in the range of a third of my time is purely on seeing customers, interacting in different ways to understand reality, right? How are we doing? What are the biggest unmet challenges that a customer is facing? Where can we be helpful? How are they thinking about the future? Right? And constantly across the leadership team and all of our colleagues, our customers know that fundamentally, we truly care about their success and we are an extension of their organization.

 

VOICE OVER: KALLUM TITCHMARSH

Drug development has grown far more complex. New approaches like cell gene therapy carry enormous promise. But turning those scientific breakthroughs into medicines requires specialized infrastructure and expertise. Thermo Fisher has increasingly expanded its capabilities to help customers manage that complexity.

 

KALLUM TITCHMARSH

Any examples come to mind from feedback driving maybe a major change in the business?

 

MARC CASPER

You know, we have been involved in the development and production of medicines for over 20 years. And over time, through the intensive interactions with our customers, what we saw was there were more modalities and more complexity coming into the biotech and pharmaceutical industry, because it wasn't just a monoclonal antibody, it wasn't just small molecule, but all of a sudden you have cell therapies and gene therapies.

And what those customers wanted was a partner that could help them manage their complexity, so they wouldn't have to be an expert in everything. And that allowed us ultimately to acquire Patheon in 2017. We could give it the resources. And the facility we're in today here in Massachusetts is one of the largest gene therapy sites in the world, and it's a site that we built from the ground up to meet customer demand. And ultimately, what you'll see here is not only, you know, the production of medicines, but you'll also see our collaboration center. You'll see how our technologies are used and how our customers can do their application work in a production setting.

 

VOICE OVER: KALLUM TITCHMARSH

Scale matters at a site like this, designed to move promising therapies from development into production and strip out the bottlenecks where time is measured in patient outcomes. That capability was put to a historic test during the Covid-19 pandemic, when Thermo Fisher mobilized across the company to expand production and support global testing almost overnight.

 

KALLUM TITCHMARSH

Maybe we can cast our mind back to 2020. Covid was obviously a really important time. How did you lead your employees through that pivot? And I'm curious whether Covid has changed the way you're thinking about the next hypothetical crisis.

 

MARC CASPER

As leaders, our job was to help shape priorities and give the team the resources they needed to be successful. And that backbone allowed us to do some extraordinary things as an organization and made a really big impact on society. Prior to the pandemic, you know, in a good year, we might be producing somewhere between 10 and 100,000 tests, right? Right? And ultimately, during the pandemic, we produced about a billion. What was special is that the team that does that work actually defined the problem set properly. So what the team figured out is, you know, what was the order of magnitude of the number of tests that might be needed to really get the pandemic under control? When you have that problem defined, you want it with a totally different set of solutions. We did some things that in six weeks, we had a factory producing stuff that you'd never be able to do in normal times. But society needed help and governments were supportive and ultimately we were able to step up to the moment and help in our small way of making a difference.

 

KALLUM TITCHMARSH

On this Thermo Fisher evolution, acquisitions have been an important part of that. What makes a company a Thermo Fisher company, and which parts of the operating model and culture and non-negotiable?

 

MARC CASPER

We've been an active acquirer over the last 20 plus years. And, you know, the way we think about it is ‘Does a company that we might acquire, does it really make the company stronger?’ And most importantly, ‘will customers value it?’ Right. When they read the press release, will their reaction be, ‘Oh that's interesting. That's an important field for me.

I want to learn more’ or is it more skeptical? And it starts with culture. Is there great pride in doing, you know, excellent work? Is it a well-run business? Right? What we're not looking to do is take broken businesses. We're looking at taking businesses and actually grow them more quickly, to expose them to more customers, to help them have the resources to scale more quickly. And it's not that we parachute a bunch of existing colleagues into the business, but we give the existing teams the resources to be successful. And it's worked well, right? And, you know, on day one of an acquisition, maybe the most important message that we give our teams are, ‘The day you joined the original company was the day you joined Thermo Fisher.’ It's not today on the day one. And we want to learn from you, and we want to benefit from your experience, and that collaboration and ownership, it really unlocks incredible potential. And we closed a meaningful acquisition in March of a company called Clario. It's used to be a technology provider for clinical development. And when you're doing a clinical study, it's really important to very easily understand how a patient is reacting to a medicine.

 

KALLUM TITCHMARSH

You have a pretty large business outside of healthcare too. Maybe tell us a bit about that.

 

MARC CASPER

You'll find our technology is used in helping environmental monitoring on the cleaner side across the world. Our technologies are used to control pollution. Technology’s electron microscopes are used to develop the next generation of semiconductors that power AI, and we're behind the scenes making that happen. The electron microscope is used in biology, but the core detection engine has many different applications.

 

KALLUM TITCHMARSH

I'm sure you're seeing a lot of demand from that at the moment.

 

MARC CASPER

Certainly with everything going on in AI, the demand is super robust for our semiconductor-related products.

 

KALLUM TITCHMARSH

One major challenge in healthcare over the next decade, what would that be and what role do you think Thermo Fisher can play in that?

 

MARC CASPER

The two things that we think a lot about and we're very engaged on is the neurodegenerative diseases, the Alzheimer's of the world and cancer. Both my mother and my older sister passed away from melanoma some years ago. And to see the breakthroughs that are available today for that disease where it was effectively a death sentence to today it is a treatable disease. You know, there are so many other cancers that are not yet in that field, and what we want to do is help our customers make as much progress as possible. So when you get that phone call or you get that message on a doctor's portal saying, you know, we need to talk, you know, you want the next sentence to say, you have this or this, but there’s a therapy out there that's going to be able to help you get through this and navigate it well. And that inspires all of us to be our very best.

 

KALLUM TITCHMARSH

Marc, I hear you were a hockey team manager at college.

 

MARC CASPER

Yeah. One of the fun things about being a manager is you quickly learn that the magic happens when the team works together. It's never about the individual, but it's about how well people collaborate and bring the best out in each other. And ultimately, that's what drives performance.

 

KALLUM TITCHMARSH

What’s the thing that, you know, you've specifically learned from that experience that you've brought into Thermo Fisher today?

 

MARC CASPER

From both the managerial and leadership perspective, you know, you serve the colleagues. You try to help them with priorities and give them the resources to be successful and in a way, stay out of the way and let them do their great work.

 

KALLUM TITCHMARSH

Indeed.

 

VOICE OVER: KALLUM TITCHMARSH

Every expansion has served the same goal, helping customers work faster, generate better data, and get breakthroughs to patients sooner. Now, like much of the industry, Thermo Fisher is looking at artificial intelligence to take more friction out of that process. You partnered with OpenAI. What can Thermo Fisher do today that it couldn't do two years ago?

 

MARC CASPER

What they're helping us do is deploy AI to make a meaningful difference to our customers. Right? So if I think about it at a high level, there's really three areas, right, which is our services business, our product business and then how we run the company. In our services business really around clinical development, you know, running clinical trials, just mining all of our historical data to identify which sites enroll patients better than others. And what that allows a customer to do is shave time out, shave cost out. Our clinical research associates will be supported by kind of an AI agent to help them make their work more effective. And so we're deploying the technologies very aggressively to help improve the process. In a way you can think about it as better, cheaper, faster. So that's area one. Area two is really around Nvidia. And as a leading provider of analytical instruments used to detect proteins to detect molecular interactions, what customers want to do is a much more high-volume set of experiments. And the more automated and the more AI-enabled our instruments are, the more insights that our customers get. And you're seeing a lot of demand for this automated type laboratory to be able to run very high-volume experimentation so that our customers are getting smarter. And then the final area is how we run the company. You know, Thermo Fisher is all about continuous improvement. We have a business system called Practical Process Improvement. We all wake up today as a colleague at the company. And basically our focus is how are we better today than we were yesterday? But the efficiency that we're getting to run the company better is quite compelling. We're just trying to be able to take lower value-added things out of the system and reinvest in things that really matter, R&D, application support, high-quality products and services, and it's a big part of our effort to make Thermo Fisher Scientific the best company it can possibly be.

 

KALLUM TITCHMARSH

Well, thank you so much, Marc. Incredible discussion. Really insightful. We really appreciate it.

 

MARC CASPER

Kallum, thanks for having me. It was really a pleasure this morning.

Watch and Subscribe:
Hosted By
  • Kallum Titchmarsh

Thermo Fisher: Extended Audio Version

Exceptional Leaders

Transcript

MARC CASPER: We live in the golden age of biology. The amount of medicines that are going through the pipeline, that are going after oncology, going after Alzheimer's, obesity-related medicines and diabetes…

 

KALLUM TITCHMARSH: While Thermo Fisher Scientific may not be a household name, its products, technologies, services and manufacturing sit behind many of the scientific advances that shape modern life — from the medicines we take and the tests doctors rely on to the advanced materials and semiconductors powering the digital world. 

 

At the center of that evolution is Marc Casper, Chairman and CEO of Thermo Fisher Scientific. Since taking the helm in 2009, he has transformed the company from one known primarily for laboratory products and scientific instruments into the world leader in serving science. 

 

TITCHMARSH: This is Exceptional Leaders, an original series from Morgan Stanley. I'm Kallum Titchmarsh, Morgan Stanley's Head of Life Science Tools and Diagnostics Research.

 

I met Casper at Thermo Fisher's biologic and gene-therapy manufacturing facility in Plainville, Massachusetts, for a look inside the operation.

 

CASPER:   Currently this is an oncology medicine that we're working on.

 

TITCHMARSH:   We sat down to talk about how Casper has built Thermo Fisher into the company it is today — how he decides where to invest, where its technologies go next, and how the company is positioning itself for the next generation of scientific breakthroughs.

 

TITCHMARSH: Marc, thank you so much for having us out here at this wonderful facility.

 

CASPER: Kallum, thanks. It's really a pleasure to be able to have this conversation with you today.

 

TITCHMARSH: If you had a minute to explain why this company matters to our everyday lives, what would you say?

 

CASPER: We're the company behind the scenes, right? And our mission is around enabling our customers to make the world a healthier place, and that enablement can be seen in developing breakthrough diagnostics that, you know, a pediatrician or, or your primary care physician would use to diagnose a complex disease, all the way through helping the pharmaceutical and biotech industry identify the new breakthrough medicines. And we take them from the molecule all the way through, commercial production of those medicines.

 

TITCHMARSH: When you took over the company in 2009, this was largely a business addressing the life sciences research community with consumables. You've since spanned way beyond that. What inspired that shift? And talk us through your game plan.

 

CASPER: We are a customer-focused, customer-centric organization. Where can we be better? Because in our industry, customers are working on ten-year journeys to bring a medicine to market, or they're working on their life's research. And so that intimacy really is important. In that deep set of customer relationships, you get new ideas and you become a trusted partner and the customer becomes open-minded to doing more with you.

 

So over time, we expanded our product offering, becoming a leading company in high technology reagents, and then we added electron microscopy. So we kind of filled out the suite of laboratory-based technologies and then ultimately expanded our services offering to help our customers be able to produce medicines, manage complexity, and then ultimately to execute the clinical trials to determine the safety and efficacy of those medicines. It's all been a journey methodically executed.

 

TITCHMARSH:  When Casper took over as CEO in October 2009, Thermo Fisher was a roughly $10 billion company built around scientific instruments, laboratory products and services. Under his leadership, revenue has grown more than fourfold. And since he took the job, Thermo Fisher’s stock has outpaced both the S&P 500 and the healthcare sector. Casper keeps a simpler measure of success, though.

 

CASPER: Probably, somewhere in the range of a third of my time is purely on seeing customers, interacting in different ways, um, to understand reality, right? How are we doing? What are the biggest unmet challenges that a customer's facing? Where can we be helpful? How are they thinking about the future, right? And this is a way of making sure that we're performing at the level that we should, understanding where future opportunities are. And constantly across the leadership team and all of our colleagues, our customers know that fundamentally we truly care about their success, and we are an extension of their organization. And that really is quite a powerful thing. My mother used to say to me, "You know, we're born with two ears and one mouth, and there's a reason for that." I think we have a culture in the organization that's very much about listening, understanding, probing, so that we have real clarity about what those big ideas are, and then passionately going after and making them a reality to help our customers do their important work.

 

TITCHMARSH: Any examples that come to mind from feedback driving, maybe a major change in the business?

 

CASPER: You know, we have been involved in the development and production of medicines for over twenty years. And over time, through the intensive interactions with our customers, what we saw was there were more modalities and more complexity coming into the biotech and pharmaceutical industry because it wasn't just a monoclonal antibody, it wasn't just small molecule, but all of a sudden you have cell therapies and gene therapies and so on and so on.

 

What those customers wanted was a partner that could help them manage the complexity, so they wouldn't have to be an expert in everything.

 

And this facility we're in today here in Massachusetts is one of the largest gene therapy sites in the world, and it's a site that we built from the ground up to meet customer demand. And ultimately, what you'll see here is not only the production of medicines, but you'll also see how our technologies are used and how our customers can do their application work in a production setting, so they can understand how to optimize the use of these technologies to help them specifically tailor these capabilities for their molecule, their medicine, so that they can make it cost effectively, quickly, and ultimately get it to patients.

 

TITCHMARSH :  Casper walks me through the drug product suite on the Plainville campus, one example of how Thermo Fisher has expanded from supplying the tools of scientific research to helping customers develop and manufacture medicines.

 

CASPER: Here we're making the active drug substance for gene therapies.

 

TITCHMARSH:  Casper and I are in standard-issue white lab coats and goggles. Through the plastic lenses, I take in rows of benches covered in delicate glass vials, and stainless steel boxes used to create a completely sterile filling environment. Around us, technicians work methodically through the highly controlled process of preparing medicines for patients.

 

CASPER: Medicine here might be, you know, seven weeks in the process itself. Um, but really a- there's months and months of preparation that happened long before it gets into the production suite.

 

TITCHMARSH: To see where that early drug development happens, Casper takes me to the Bioprocess Design Center. There, drug makers work alongside Thermo Fisher scientists and engineers to test ideas and work out production problems before scaling up to full manufacturing.

 

CASPER: When you look up into the ceiling — that is a 5,000-liter bioreactor, the highest-volume single-use technology in the world. It's a multi-story machine, laid out almost on the length of a tractor-trailer bed.

 

And it really has been profound. It's called single-use because you have a set of films that keep the medicine independent of the reactors. And what that allows you to do is have very low-cost ways to change over to the next batch. And as opposed to a multi-billion-dollar facility that’s using stainless-steel and a lot of technology to clean it, you effectively produce in a bag for a certain number of weeks, and then very quickly you can turn it over to the next medicine.

 

TITCHMARSH:  The medicines developed here are bound for hospitals, research labs, and clinical trial patients. When these therapies are ready for more intensive production, they may move into the drug product suite, to be produced at scale and distributed multinationally. Thermo Fisher’s pharma services network spans more than 60 sites across 25 countries—a global footprint that was tested like never before during the global pandemic.

 

TITCHMARSH: Maybe we can cast our minds back to 2020. COVID was obviously a really important time for the company. Right. How did you lead your employees through that pivot? And I'm curious whether COVID has changed the way you're thinking about the next hypothetical crisis.

 

CASPER: I spent a lot of time periodically reflecting on that. It was a level of intensity that even in an intense career really was at a different level. As a leader, and, and the leadership team broadly felt similarly: the colleagues actually knew what to do, right? And I remember very early in the pandemic, one of our large customers called me to thank me, and I'm like, "For what?" And he said, "You know, we were producing an important medicine—nothing to do with the pandemic—and supply chains had been disrupted, and your team locally in the Netherlands found a solution for us and we weren't disrupted in terms of production.

 

And that example really happened tens of thousands of times during the pandemic. As leaders, our job was to help shape priorities and give the team the resources they needed to be successful, right? And that backbone allowed us to do some extraordinary things as an organization.

 

About a third of all the PCR testing, globally, was run on our technology. And prior to the pandemic in a good year we might be producing somewhere between 10 and 100,000 tests. And ultimately, during the pandemic, we produced about a billion. What was special is that the team that does that work actually defined the problem set properly.

 

Because if you ask the question: you're making, say, 100,000 tests a year, how many can you make? If you made a million, you say, "That's great," It's 10 times the thing, but it wouldn't make a difference whatsoever. So what the team figured out is, you know, what was the order of magnitude of the number of tests that might be needed to really get the pandemic under control? And they started throwing out a number like a billion plus. And when you have that problem defined you wind up with a totally different set of solutions. We actually built a factory during the pandemic. In six weeks we had a factory producing stuff that you'd never be able to do in normal times. But society needed help, and governments were supportive, and, and ultimately we were able to step up to the moment. It wound up being this time where all of our resources, and most importantly all of our colleagues totally engaged to make a real difference from a societal standpoint.

 

TITCHMARSH: If you could solve one major challenge in healthcare over the next decade, and what role do you think Thermo Fisher can play in that?

 

CASPER: Yeah, I mean, the two things that, um, we think a lot about, and we're very engaged in are the neurodegenerative diseases, the Alzheimer's of the world, and cancer. And so both are areas that we wanna see huge breakthroughs happen in enabling our customers to make progress. And when I think about oncology, um, you know, it's something that I take, um, very personal. Both my mother and my older sister, um, passed away from melanoma some years ago, and to see the breakthroughs that are available today for that disease where, where it was effectively a death sentence to today, it is a treatable disease. There are so many other cancers that are not yet in that, uh, in that field, and, and what we wanna do is help our customers make as much progress as possible. So when you get that phone call, or you get that message on a doctor's portal saying, you know, "We need to talk," you know, you want the next sentence to say, "You have this, but there's a therapy out there that's gonna be able to help you get through this and navigate it well." And that inspires all of us to be our very best.

 

TITCHMARSH: That instinct — to bring out the best in the people around him didn't start at Thermo Fisher. It began much earlier for Casper.

 

TITCHMARSH: Marc, I hear you were a hockey team manager at college.

 

CASPER: Yeah, my passion about hockey was a lifetime ago. You know, one of the fun things about being a manager is you quickly learn that the magic happens when the team works together. It's never about the individual, but it's about how well people collaborate and bring the best out in each other. And ultimately that's what drives performance. So, it's learning early on a life lesson and trying to apply it over the years.

TITCHMARSH: And the thing that you've specifically learned from that experience that you brought into Thermo Fisher today?

 

CASPER:  From both the managerial and leadership perspective, you know, you serve the colleagues or you try to help them with priorities and give them the resources to be successful and in a way, stay out of the way and let them do their great work they do.

TITCHMARSH: You have a unique vantage point across many different regions, different funding environments, fueling innovation in different ways. What do you think the most successful ingredients are for a healthy innovation system?

 

CASPER: As a truly global company, with 125,000 colleagues working around the world, we have a really good feel for the different regions around the world and their unique attributes. When I think about the US, the ability to raise capital and take an idea into company formation and ultimately bring it to market, it really is unique. The strength of the academic medical centers and the university system that we have is really quite compelling.

 

When you go to Europe, you have really incredible scientific and engineering expertise, right? World-renowned. And if I think about some of our breakthroughs in instrumentation that come out of Germany, that come out of the Netherlands, Czech Republic, right? Just incredible talent that's pushing science.

 

And then when you turn to Asia Pacific, you see a focus on speed, an incredible intensity. It’s all about shaving time out of the process. It's about deploying automation, AI, and when I think about all of that, what we really try to do is share some of the best practices around the world and, ultimately, pick the best thinking because innovation can happen anywhere, and the more cost-effectively it can be brought to market, the better off the world's gonna be.

 

TITCHMARSH: Acquisitions have been an important part of that. What makes a company a Thermo Fisher company, and which parts of the operating model and culture are non-negotiable?

 

CASPER: We're in a fragmented industry. We've been an active acquirer over the last twenty-plus years. The way we think about it is, does a company that we might acquire, will customers value it, right? When they read the press release, will their reaction be, "Oh, that's interesting. That's an important field for me. I want to learn more," or is more skeptical. But the  truly non-negotiable is it has to generate strong shareholder returns, right? And we look at a few things. One is we characterize risk, right? We wanna understand what could go wrong, and could we live with [that] financially? We want to know that what we're buying is really gonna be something that even in a scenario that doesn't play out the way we want, that it's gonna be acceptable.

 

And to determine risk and really do that, you get to the question that you have, which is: What makes a Thermo Fisher company, right? And it starts with culture, right? Is there great pride in doing, you know, excellent work? Is it a well-run business, right? What we're not looking to do is take broken businesses. We're looking at taking businesses and actually growing them more quickly, to expose them to more customers, to help them have the resources to scale more quickly. And it's not that we parachute a bunch of existing colleagues into the business, but we give the existing teams the resources to be successful, and it's worked well, right?

 

On day one of an acquisition, maybe the most important message that we give our teams are, "The day you joined the original company was the day you joined Thermo Fisher. And we want to learn from you, and we want to benefit from your experiences. And that collaboration and ownership, it really unlocks incredible potential. We're proud of our track record, and we know that we, from a shareholder perspective, we gotta earn it every day. We closed a meaningful acquisition in March of a company called Clario, a technology provider for clinical development. When you're doing a clinical study, it's really important to very, very easily understand how a patient is reacting to a medicine, and this technology platform is ubiquitously used in that area.

 

TITCHMARSH: As Casper notes, there's been a steady stream of mergers and acquisitions, which is fitting for a company born from the combination of Thermo Electron and Fisher Scientific in 2006. Over the years, those deals have expanded Thermo Fisher’s capabilities across areas ranging from life sciences and specialty diagnostics to clinical research and drug manufacturing.

 

This range is important, because scientific discovery feeds on itself: a breakthrough in one area opens up a discovery in another. By having its tools in labs almost everywhere, Thermo Fisher is able to connect industries and disciplines.

 

TITCHMARSH: You have a pretty large business outside of healthcare to maybe tell us a bit about that.

 

CASPER: You'll find our technologies used in helping environmental monitoring on the cleaner side. Across the world, our technologies are used to control pollution, and in material science, breakthroughs in semiconductors.

 

TITCHMARSH:  As we walk along a corridor, Casper stops in front of a giant metal tube about half my size. He explains how this piece of equipment is now used well beyond what it was initially built for.   

 

CASPER:  The electron microscope was used in biology, but the core detection engine has many different applications. How the form and feature is quite different in a semiconductor fab versus in a, you know, in a life sciences facility like this one. But nonetheless, the core technology is the same. You know, we're behind the scenes making that happen.

 

TITCHMARSH: I'm sure you're seeing a lot of demand from that at the moment.

 

MARC CASPER: Certainly, with everything going on in AI, the demand is super robust for our semiconductor related products.

 

TITCHMARSH: As semiconductors shrink, older tools can't keep up. That's where Thermo Fisher’s fully automated electron microscope comes in. Lining up a sample that small by hand is nearly impossible, so the machine does the setup itself. That makes data collection faster and more precise.

 

TITCHMARSH: You've partnered with OpenAI. What can Thermo Fisher do today that it couldn't do two years ago?

 

CASPER: What they're helping us do is deploy AI to make a meaningful difference to our customers, right? So if I think about it at a high level, there's really three areas, right? Which is in our services business, our product business, and then how we run the company. In our services business, really around clinical development, you know, running clinical trials, because it's a very multi-year long process, incredibly data intensive: just mining all of our historical data to identify which sites enroll patients better than others, which areas have more likely to have the patient population you're looking for, it streamlined the clinical development process. And what that allows a customer to do is shave time out, shave cost out.

 

Our clinical research associates will be supported by an AI agent to help them make their work more effective. And so we're deploying the technologies very aggressively to help, you know, improve the process in a way you can think about it as better, cheaper, faster. And it's meaningful, because the single most capital intensive part of developing a drug is actually on the clinical development side.

 

Area two is really around NVIDIA and as a leading provider of analytical instruments used to detect proteins, detect molecular interactions…what customers want to do is a much more high volume set of experiments. In a way, they're trying to populate biological models so that they can identify the next generation of drugs. And the more automated and the more AI-enabled our instruments are, the more insights that our customers get, and you're seeing a lot of demand for this automated type laboratory to be able to run very high volume experimentation. So it's a super interesting time in terms of creating a reinvestment cycle, um, in the basic infrastructure used to do scientific research.

 

And then the final area is how we run the company. You know, Thermo Fisher is all about continuous improvement. We have a business system called Practical Process Improvement. We all wake up today and basically our focus is: how are we better today than we were yesterday? And AI is an incredible enabler, and we all know that from all of the ways we use it in our daily lives, but the efficiency that we're getting to run the company better is quite compelling.

 

We're just trying to take lower value-added things out of the system and reinvest in things that really matter: R&D, application support, high quality products and services. And, um, it's a big part of our effort to make Thermo Fisher Scientific the best company it can possibly be.

 

TITCHMARSH: Well, thank you so much, Marc. Incredible discussion. Really insightful. We really appreciate it.

 

CASPER: Kallum, thanks for having me. It was really a pleasure this morning.



TITCHMARSH: Across nearly two decades, a pandemic, and a significant number of acquisitions, the throughline of Casper's leadership holds: support your team where they need it, and then get out of the way.

 

As we enter a new era of scientific discovery — powered by AI-run instruments, faster trials, and therapies that target the root causes of our toughest diseases — those emerging breakthroughs will be built on the groundwork Thermo Fisher has already laid.

 

Thanks for listening to Exceptional Leaders from Morgan Stanley. For the video version of this conversation, visit morganstanley.com or our YouTube channel. And be sure to rate, review, and subscribe wherever you get your podcasts.

Exceptional Leaders

In this engaging series from Morgan Stanley, experts from across the firm sit down with leaders at world-class companies for insightful conversations covering everything from leadership lessons to foundational changes in industries, markets and society.

Hard Lessons Series Artwork

Up Next

The success of India’s transformation isn’t just about building rail lines, data centers or chip f...

Transcript

MINISTER VAISHNAW

When we say democratized technology, we mean that technology should not be left in the hands of a few. It should be accessible to a wide section of the society, and people should be able to use them, create solutions, and make a difference in their own lives.

 

RIDHAM DESAI 

India is the world’s fifth-largest economy, and it’s building at a pace and scale that few countries have attempted simultaneously: new rail corridors, a nationwide 5G rollout, a fast-growing electronics export sector, and an ambitious push into AI and semi-conductors, all at once. One of the architects of this transformation is Ashwini Vaishnaw, India’s Minister for Railways, Electronics, and Information Technology. An engineer and former entrepreneur, Minister Vaishnaw oversees two of the country’s most consequential platforms: the rail network that moves billions of passengers and millions of tons of cargo every year and the digital infrastructure that underpins data, payments, and compute for a country of nearly of nearly 1.5 billion people. As Head of India Research and Chief India Equity Strategist, I was curious to learn more about what it takes to lead ambitious change in a country as large and diverse as India. So I sat down with Minister Vaishnaw in his offices in New Delhi to talk about what it takes to modernize a country’s physical and digital backbone and what this means for India’s continued development.

 

DESAI

It's great to have you here, Minister Vaishnaw, on Exceptional Leaders.

 

MINISTER VAISHNAW

Thank you, Ridham, for having me here.

 

DESAI

You have been at the helm of what I would consider as the world's largest scale transformation: Indian Railways. How did you do this? And that too, in such a short span of time?

 

MINISTER VAISHNAW

It is a very complex organization and a very large organization: 1.2 million employees, 135,000 km of railway track, 7.4 billion people traveling on the network. Very complex network. The biggest challenge that we faced was to understand how this organization operates and then find out where the constraints are, then making sure that the solution is accepted by the people, and then go forward. Everywhere we looked at, “What is the constraint? What are the problems?” Go down to the root of the problem. Solve for the root. Whether you have to make a change in the process, whether you have to make a change in technology, whether you have to make a change in the machines which are used, whether you have to make a change in the training: it's like going deep dive practically in every part of this huge, big organization.

 

DESAI

How critical is this transformation to India's manufacturing aspirations? And also on tech diffusion?

 

MINISTER VAISHNAW

Manufacturing competitiveness has logistics cost and logistics efficiency as a major element. And when we are improving the railway operations, this is directly impacting the cost of logistics and the efficiency of logistics. A decade ago, we used to carry just about 1,000 million tonnes of cargo. Today, we are carrying 1,670 million tonnes of cargo. This directly impacts the way industries operate. If the industries are located close to a railway terminal, then it becomes very easy for them to manufacture straight away, put it on the wagons, and ship it to the place they would like it to go.

 

DESAI

India now operates one of the largest rail freight networks and one of the largest 5G ecosystems in the world and has done both on an impressive timeline. The Minister makes the case that these aren’t separate initiatives but a single coordinated growth engine. The question now is whether India can extend that momentum into the next frontier: artificial intelligence.

 

DESAI

On the two foundational networks you run: rail and digital. At first sight, they seem very different from each other, but they do intersect.

 

MINISTER VAISHNAW

They look very different, but basically, they are part of that same growth strategy that India is following for the last decade. These two networks are basically increasing India's productivity, improving the efficiency in our economy, and third, they are making a big difference in people's lives. Railway: today, we are the second-largest goods career in the entire world. If we invest in this network, then it makes a huge difference in the growth. Second, it is bringing the logistics efficiency. Third, we can have affordable travel for our people.

 

If you look at this Vande Bharat Express: designed in India, made in India, semi-high-speed 180 km/h speed potential. We are able to provide this kind of service at 2.3 cents a kilometer. Go to China: it is about seven times. Go to Japan: it is about ten times this price. Go to Europe: it is about twenty times. So we are able to provide very good service at a very affordable price at the income level at which we are in our country today.

 

Same is the case of the digital network. We focused on making sure that 5G reaches every part of the country. Practically 90% of the country has 5G today: second-largest 5G ecosystem in the world. And look at the digital public infra, the payment system, the DigiLocker, the document management system: all these things have ensured that our people get the benefits of digital economy, which normally would have accrued only to the developed countries. So both sectors in that sense are very important for India's growth and very important for making a difference in people's lives. So that way they are interconnected.

 

DESAI

What is it that India is doing on AI? The world seems to have the view that India is falling behind. Would you agree, disagree, and how would you inform that view?

 

MINISTER VAISHNAW

Our biggest strength is in the applications layer. The biggest strength of our IT industry is to go into any enterprise, understand the enterprise, understand the operating system of the enterprise, and provide a solution based on that operating system. Almost 80% of the startups which are coming up now are basically providing AI-based solutions. The second layer in which we are playing well is the data center. We are one of those few countries which have more than half the power generation capacities from clean power: about 250 gigawatts is from renewable energy sources.

 

DESAI 

A decade ago, mobile phones ranked168th on India’s export list. Today, they’re number one. That trajectory is now being applied to semiconductors, where India already accounts for 20% of the global chip design workforce. For investors watching supply chain diversification away from China, this is one of the most significant manufacturing stories in the emerging world.

 

DESAI

The success that we have had in electronics is unbelievable. Ten years ago, phones was 168th on our list of export items. It is now number one. What has driven this success, and is this the template for semiconductors for chips?

 

MINISTER VAISHNAW

We started electronics manufacturing in a very, very methodical way. We started with getting the finished products assembly in our ecosystem. Then we went to the module level, then we went to the submodule level, and now we are at the component level. So step-by-step, building this entire ecosystem. Because of this strategy, in a period of [the] last decade, we have been able to establish ourselves as an important electronics manufacturing destination.

 

The second big advantage that we have is the trust that the world has on India. We have a very strong copyright and IP right protection system. The third point is our capabilities in design. We are a country which is where our engineers are designing products for practically the entire world. That has given us the template which we are using in multiple sectors, for example, in the case of semiconductors. In the case of chip manufacturing, we focused a lot on the design capabilities, which where we are very strong already. Already 20% of the global design workforce is in India, so we decided to take it to a totally, totally next level. So we gave the best of the design tools to 318 universities now. The students are using Synopsys, Cadence, and so many other tools. These are the chips designed by students. Look at the names of the places: Kolkata, Surat, Jalandhar, Gwalior, Indore. Throughout the country, these chips are manufactured in a semiconductor laboratory. In that laboratory, the chips are manufactured, fabricated, and then they are assembled, and the final chip is tested so the students get to see the result of what they have designed.

 

DESAI

You have often said that we need to democratize technology. What does that exactly mean, and how is it informing India’s progress in technology?

 

MINISTER VAISHNAW

When we looked at the 5G rollout, we decided that we will not limit 5G to the big cities, but we will make sure that 5G goes out to the villages. So practically 90% of the country is today covered under 5G. When we created this DPI structure, the entire structure is built in a way that, let’s say, the payment system: it should not be monopoly of one or two companies. It should be any startup which wants to come up with a new solution. They must get the opportunity to prove their solution.

 

DESAI 

The ground level input that the Minister’s office is capturing on these reforms is in service of a broader goal. 2047 marks the 100th anniversary of India’s independence, and the Indian government has made it the target date for what it calls Viksit Bharat, or Developed India, a national vision to transform the country into a fully developed economy.

 

DESAI

How do you see India’s transformation? How will it look like in 2047?

 

MINISTER VAISHNAW

We have taken a target of making our country as a developed nation, then converting that target into sector-specific goals, then looking at a short-term, medium-term, long-term strategy, then building those, that basic growth engine, which is built on the four pillars: investment in physical, digital and social infra, inclusive growth, focus on innovation, and manufacturing.

 

That kind of thinking and that kind of execution is helping us move consistently in our journey towards a developed nation. More than 250 million people have come out of extreme poverty in the last decade. That’s a huge achievement for the country. We will become leaders in some of the technologies that we have selected for us. We will have equal opportunities for a large section of this society. In 2047, we’ll be 37 years median age. We will still be a young country at 2047, when we will be about anywhere between $25 to $30 trillion economy, and we will have another 50 years of growth ahead of us because of our demography. So all these factors together, and the foundation that is being built today, will give us that growth path for the many decades going forward.

 

DESAI

It's fantastic. Okay, my final question. Are there any projects, either personal or professional, that you are going to tackle next?

 

MINISTER VAISHNAW

Developing the 350 km/h bullet train is on top of my agenda. So it is very important to have this entire technological base in our country.

 

And second, going to the seven nanometers from 28 nanometers. That's again going to be a very big challenge for the country because between seven nanometer and 19 nanometers, we will have practically maybe 85% of the entire volume of semiconductor chips. So making sure that that much capability of the country is developed in the next few years.

 

These two are the most complex ones which I am working on. On personal front, I am very focused on reducing my weight to 69 kilos. Be like you: fit always.

 

DESAI

Thank you, Minister Vaishnaw, for this really insightful conversation. It was great having you on the show.

 

MINISTER VAISHNAW

Same here. I thoroughly enjoyed the conversation, Ridham. Thank you so much for having me here. Thank you.

India's Minister for Railways, Electronics and Information Technology
Leading a global airline isn’t just about overseeing complex operations in an environment of near-...

Transcript

SCOTT KIRBY

Most people confuse management and leadership. If you can inspire 120,000 people with a vision, you can accomplish a whole lot more than if you’re going through a checklist every day.

RAVI SHANKER 

Since its inaugural flight a century ago, United Airlines has defined commercial air travel, with a history of firsts, spanning everything from the modern airliner and flight attendants to computerized flight planning. Today, United connects more people to more destinations than any carrier on the planet. But it isn’t just about growth; United is focused on improving the travel experience for all passengers. Behind this vision, CEO Scott Kirby has spent his career thinking differently about what it means to run and lead an airline. When the industry was impacted by Covid, United invested for growth and emerged stronger. Even as corporate boards began confronting deglobalization, Kirby leaned into international expansion. And now, as many leaders view AI as a way to cut headcount, Kirby sees technology as a way to improve human interactions, not replace them. As Morgan Stanley’s lead North American airlines analyst, I want to learn more about how Kirby makes decisions in an industry that faces constant uncertainty. So I traveled to United’s headquarters in Chicago, where I sat down with Kirby on the day United turned one hundred and got a close look at Kirby’s approach to leadership and discussed some Sambas.

RAVI

Thank you, Scott, for having me here today on the actual one hundredth anniversary of United. Congratulations.

SCOTT

Yeah, today’s the day: a hundred years.

RAVI

Happy birthday!

SCOTT

Thank you. And how do you like the shoes? Hundred-year anniversary Sambas.

 

RAVI

That is fantastic. You graduated from the Air Force Academy. Did you originally aspire to fly professionally? And what prompted you to go a different direction?

 

SCOTT

I went to the Air Force Academy intending to be a pilot and then an astronaut, and while there, you get to fly, and I was out in an F-4—dogfighting, aerial, broke the sound barrier-

 

RAVI

Wow.

 

SCOTT

-and at the end of it, the pilot told me to close my eyes and fly straight and level by feel, and I was at a 30-degree left bank and he said, “Use the instruments,” and I did, and I felt like I was going to fall out of the seat to the right, and he laughed at me and said, “You’re never going to be a fighter pilot. You’re going to be a cargo pilot.” And that moment, I decided, “I’m sure you’re right about the first one, but you are dead wrong about the second one.” So I didn’t go to pilot training.

 

RAVI

To the present day: you may not be a fighter pilot, but you operate in an environment of near-constant volatility. So how do you handle the daily realities of this environment we are in right now?

 

SCOTT

You’re trying to figure out on the fly what’s going to happen, trying to look over the horizon, trying to read extensively—I’ve done that my whole life, I read three hours a day on average—but I’m genuinely curious, and when you do that, you connect the dots I think that other people can’t connect and don’t see. I think this has happened a lot of times in my career: to try to see things earlier and how to take advantage of stuff when I have a view that is different than the consensus view.

 

 

RAVI

How do you carve out the space and time to think long term, with everything going on?

 

SCOTT

I’m really good at time management, and I don’t waste time: in my personal life, professional life, I’m not on social media—what a time suck—I don’t really watch TV, another time suck. But in business, less than four hours of meetings a day on my calendar is my rule. It gives you time to think, it gives you time to read, it gives me time to just call people and ask questions, but also, I have a great team. And I feel like if I am trying to micromanage, I’ve done something wrong.

 

RAVI

You’re known as a highly data-driven leader. So as data has become more pervasive, has your approach to leadership changed as well?

 

SCOTT

I don’t think it’s changed so much because of data—in fact, I probably use data less explicitly the further I go in my career. I could tell you pretty close what it’s been for the last thirty days; I know about the operation; I know what we’ve done; I know what each of the other airlines have done. But I really use that more to paint the palette of thinking about other bigger decisions. And I draw a big distinction between management and leadership.

Management is about compliance; it’s about running the checklist: how many people showed up for work on time. But leadership is different; it’s about inspiration and vision. And compliance is really important; you need people to do that. But leadership is more rare.

The further you move up anywhere in your career, the more your job indexes from management functions to leadership functions.

 

RAVI

Is that your leadership version? Did you have a mentor? How did you, kind of frame that?

 

SCOTT

I’ve learned a lot more from watching people make mistakes. And I’ve learned a lot, more of the positive examples, from reading: you know, Winston Churchill’s top of my list of heroes. You know, like, what would Winston Churchill do in a situation like this? Abraham Lincoln is another one. But I also learn from myself too, like mistakes that I’ve made, like you make a mistake like, “To thine own self be true,” what a great line. When you screw something up, like I don’t mind making a mistake; I hate making a mistake twice.

 

 

RAVI

What are the feedback systems that you have, to maybe see some of the things that you're not seeing?

 

 

SCOTT

You have to spend a lot of time out, talking with people. I have the easiest job of anyone at United because I have only really one responsibility: create a company that our employees are proud of. And so I look for that pride, and I spend a lot of time out in the operation, you know, I—every week I'm out, you know, either virtually or in person, talking to groups of new captains and talking to groups of new pursers at United, and you can tell if people feel proud of the company. People want to be on a winning team, and winning is contagious.

 

 

RAVI

Can you give us an example of an instance where the data pointed one way, but your gut or instinct kind of said there was something different?

SCOTT

 

Covid. You know, when Covid started, the data to me pointed to like, this is a global pandemic, and it was hard for me to understand why no one else knew it. We were just a couple weeks ahead of the globe-

 

RAVI

-you were the first.

 

SCOTT

-but, you know, we went off and raised two billion dollars at three percent interest two days before the NBA walked off the court and it would’ve been impossible, and we shrunk more than everyone else quickly. But then during Covid, the data got wrong. All the experts believed that air travel demand would never recover, and all the surveys—if you did surveys—people said they were never going to fly again.

And so, literally every global long-haul airline in the world, except United, permanently retired part of their global long haul wide-bodied fleet and shrunk. And we looked at that, and I said, “I think that’s just the wrong decision.” Instead, we did the biggest aircraft orders in history during Covid.

 

RAVI

If you were not the CEO, what job would you like to have and why would you be good at it?

 

 

SCOTT

The foundation of an airline is the route network. That is our asset. You have to learn the whole airline; you have to learn what makes it tick, what makes it work, what makes it profitable, what doesn’t work, what works operationally. You really have to learn the whole network to be good at route planning.

 

 

RAVI

Global expansion is obviously a major focus for United. You fly to 385 destinations globally. What are some of the unique challenges and opportunities?

 

 

SCOTT

Flying globally is—it’s what customers want, so that's the starting point. But it also creates unique challenges and opportunities. I mean, you know, we're just exposed to everything that happens anywhere in the world. You know, if there's war in the Middle East, you know, we're not just hit by fuel prices, we fly to those places. When the war in Ukraine started, we, you know, flew over Russia. Anytime something happens in the globe, we're exposed to it, but it's where our customers want.

When you’re an airline as large as United, it actually—to find new destinations, it means that we can’t just use data. We’re flying to places like Nuuk, Greenland, which no US airline has ever flown to. And so, you have to find other sources and other ideas and make bets on what will work. This summer, we’re starting two destinations in Spain and Portugal that are part of pilgrimages: where people fly into Lisbon and they walk two hundred miles to another destination. We’d seen a lot of one-way traffic in but not return traffic in and realized that, and it’s been booked up like crazy, so it’s done really well.

 

 

RAVI

What gives United an edge when it comes to recruiting pilots, flight attendants, or anybody else who wants to work for United, and kind of pass that culture through?

 

 

SCOTT

We really are at the top of the food chain for aviation and for industries at large. We're growing faster every year in absolute than any airline in history has done, which gives you lots of opportunities. And if you come to United, it feels like you're on the winning team. I just came from speaking to a group of new hires. We had people from all of the major airlines. A lot of them were talking about, “In my area, United is doing this, and you're the leader here.” And so they're all excited to come. People that come to United are usually coming for a career. We still create the kind of careers that used to be common in the United States. But, you know, a pilot, a mechanic, a gate agent, you know, can start here when they're twenty years old. And when they get to the top of the scale, and certainly with a little bit of overtime, they can make six digits; they have great benefits; you know, they can work for a lifetime. They can buy a house; they can send their kids to college. It's an important part of the fabric of America. And being able to create those kinds of careers, it’s—we're proud to do it.

 

 

RAVI

Just given the thought and effort you guys put into recruitment, kind of how does that translate into customer experience? Kind of that culture of United coming through?

 

 

SCOTT

What we've tried to do is actually hire people for attitude, instead of hiring for technical skills. We can train someone to be a flight attendant. We can train someone to be a gate agent. What we can't train is to be a people person that cares. So we try to hire people that have that attitude that are really our “people people.” I mean, we're in the business of connecting people and uniting the world.

 

 

RAVI

The premiumization of air travel is a major theme in the industry, kind of a big change versus the last decade. So how is United kind of building brand loyalty across all segments?

 

 

SCOTT

So I pushed back actually a little bit on the premiumization of the industry. It is happening, but I start by saying, “We're investing nose to tail for all customers.” And I think that actually the gap between our Economy and other airlines’ Economies is probably bigger even than the gap between Premium to Premium; there's a gap in both places. But, you know, with things like Starlink throughout the airplane, seatback entertainment throughout the airplane, the app—you know, we have the best technology of any airline in the world, the app. Anyone that uses it knows it. So we're really focused on creating products, technology service that all customers like. We have a lot of Premium demand, and we’re investing more heavily. You know, the latest 797, you know, I think is probably the best airplane flying in the Western world. The CRJ 450, you know, when you're flying to small cities, you know, it's like flying on a private airplane. It's the opposite trend of what most airlines do, and we took 18% of the seats off the airplane.

 

 

RAVI

So when it comes to innovation, kind of either on board or on the ground or offline, how do you come up with kind of innovative new ideas in terms of customer offerings?

 

 

 

 

SCOTT

I try to go by the philosophy that Henry Ford had and Steve Jobs had. Henry Ford said something along the lines of, “If you ask people what they want, they’d tell you, a faster horse.” And Steve Jobs famously eschewed any kind of consumer survey stuff because he wanted to invent something that they didn't know they wanted yet. Some of the things that we put in the app are not the kind of things that people ask questions about. You know, we put a scorecard in for frequent fliers last year: How many flights did you take? How many hours? How many miles did you fly? We’ve started putting the airport map, so you can see when you're on the ground where you have to taxi.

I want us to surprise and wow our customers every year with something new. So then they get on the airplane, they say, “I've never seen an airline do that; I never even thought of this before.” So we're trying to figure out what people will love, even if they haven't asked for it yet.

 

 

RAVI

You just added the TSA wait times to the app. I didn't know that was possible.

 

 

SCOTT

We've also added technology on the app that if you opt in, we’ll track you, so we can know to wait for you for connecting gates. We want to do things like deliver food to your gate, if you need a connecting flight and you want to be able to order food. But one of the other things is, it'll give real time waits, trying to get really real-time data to customers, and we're the only airline that’s doing it.

 

 

RAVI

Moving to the topic of AI. So how does AI improve how United operates? And what does that mean for your passengers?

 

 

SCOTT

It's a great tool. It's going to do a lot of things—it does do a lot of things—really well. But I do not think that the primary use case of AI is replacing the work that everyone does. And if that's the primary use case, like, it's for sure a bubble, because we're spending way too much for that. Too many people are getting dependent on AI, and like thing that people are using AI for is summarizing documents. Like, that seems to me to be the number one use case. I actually want to read the book. Because all the cool learnings are, you know, on page 312 in a little paragraph that there's some cool insight, and I think you're going to miss all that.

The cool thing about AI is the things that you can do that were impossible or impractical before. One of my favorite examples is, anytime there's a delay or cancellation, I want the team to pretend I'm on the airplane and I've called the network operating center: “Why is my flight delayed?” Whatever they would tell me, I want to tell customers 100% of the time. We're better at it than any other airline in the world, but we're not even into the game yet. We're still in the pre-game. [It’s] really hard to do without AI. It's also going to help us, I think, in our network operating center, when we’re deciding which flights—when stuff happens, you know, when weather hits and airports close, like it's one of those problems that has multiple tentacles that can last for days: crew and maintenance and all kinds of other implications. And they're all stochastic, like you know, you don't know for sure what's going to happen down the line.

 

 

RAVI

Scott, you mentioned that Covid was an instance where the data pointed one direction, but your instinct took another direction. What is that moment today?

 

 

SCOTT

Oh, oil prices and the war in Iran. From the time that MEU left Asia for the Middle East, I thought the forward curve was wrong. I thought oil was going to be higher for longer. And so we’ve been preparing for that at United. The experts that I talked to back then all told me: worst case, the Straits of Hormuz are open by the end of March. I think oil prices are going to be higher for longer. We at United are preparing for that. That's our base case planning assumption. I think there may be an opportunity to take advantage of it when our competitors are managing more by hope instead of reality.

 

RAVI

Scott, so when you eventually do step out of the CEO role, what do you hope people would say that you changed about United and the industry?

 

 

SCOTT

I want to have United to have launched a new era in aviation—what it means to be an airline. A lot of it's going to be technology—the technology that takes all of the uncertainty and stress of travel. Make travel fun. And my second one is to leave behind a CEO who's better than me.

 

 

RAVI

Well, we won’t be making that change anytime soon. Scott, thank you for joining us. It has been real fun.

 

 

SCOTT

Thank you.

 

 

 

RAVI

Appreciate it.

 

 

Wellhub

More from Morgan Stanley